Fig. 1.

Schematic representation of TPGS-coated cationic liposomes with Bcl-2 siRNA-corona to load doxorubicin (Dox). (A) The preparation process and the structure of Bcl-2 siRNA/Dox-TPGS-LPs. (B) Overcoming MDR by combined inhibition of P-gp pump and Bcl-2 protein with Bcl-2 siRNA/Dox-TPGS-LPs. I: Dox release in cytosol and uptake in nuclei; II: Released Bcl-2 siRNA in cytosol to trigger RNA-induced silencing complex (RISC) for eliminating Bcl-2 mRNA to down-regulate the expression of Bcl-2 protein; III: Released TPGS to inhibit drug-efflux P-gp pump.